A Randomized Double-Blind Multi-Centre Study to Evaluate the Eficacy and Safety of Zometa as a Treatment in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Zoledronic acid (Primary) ; Pamidronic acid
- Indications Cancer metastases; Multiple myeloma; Solid tumours
- Focus Therapeutic Use
- Sponsors Novartis
- 09 Oct 2008 Official title amended as reported by ClinicalTrials.gov.
- 21 Sep 2006 Status change from recruiting to completed
- 24 Dec 2005 New trial record.